- Home
- BCDA vs EDUC Comparison
BCDA vs EDUC Comparison
Compare BCDA & EDUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- EDUC
- Stock Information
- Founded
- BCDA N/A
- EDUC 1965
- Country
- BCDA United States
- EDUC United States
- Employees
- BCDA N/A
- EDUC N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- EDUC Consumer Specialties
- Sector
- BCDA Health Care
- EDUC Consumer Discretionary
- Exchange
- BCDA Nasdaq
- EDUC Nasdaq
- Market Cap
- BCDA 11.3M
- EDUC 11.4M
- IPO Year
- BCDA N/A
- EDUC N/A
- Fundamental
- Price
- BCDA $1.56
- EDUC $1.58
- Analyst Decision
- BCDA Strong Buy
- EDUC
- Analyst Count
- BCDA 1
- EDUC 0
- Target Price
- BCDA $25.00
- EDUC N/A
- AVG Volume (30 Days)
- BCDA 46.4K
- EDUC 322.9K
- Earning Date
- BCDA 11-12-2025
- EDUC 10-09-2025
- Dividend Yield
- BCDA N/A
- EDUC N/A
- EPS Growth
- BCDA N/A
- EDUC N/A
- EPS
- BCDA N/A
- EDUC N/A
- Revenue
- BCDA N/A
- EDUC $31,304,000.00
- Revenue This Year
- BCDA N/A
- EDUC N/A
- Revenue Next Year
- BCDA N/A
- EDUC N/A
- P/E Ratio
- BCDA N/A
- EDUC N/A
- Revenue Growth
- BCDA N/A
- EDUC N/A
- 52 Week Low
- BCDA $1.63
- EDUC $0.92
- 52 Week High
- BCDA $3.25
- EDUC $2.49
- Technical
- Relative Strength Index (RSI)
- BCDA 30.27
- EDUC 80.56
- Support Level
- BCDA $2.11
- EDUC $1.08
- Resistance Level
- BCDA $2.29
- EDUC $1.16
- Average True Range (ATR)
- BCDA 0.12
- EDUC 0.09
- MACD
- BCDA -0.03
- EDUC 0.05
- Stochastic Oscillator
- BCDA 0.96
- EDUC 87.90
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.